Viatris (VTRS) Common Equity (2019 - 2026)
Viatris' (VTRS) quarterly Common Equity came in at $14.7 billion in Q1 2026, down 6.34% year-on-year from $15.7 billion in Q1 2025, and little changed quarter-over-quarter from $14.7 billion in Q4 2025.
Viatris (VTRS) Common Equity (2019 - 2026) Analysis & Trends
Viatris' Common Equity history runs 8 years deep, the most recent figure standing at $14.7 billion for Q1 2026.
- On a quarterly basis, Common Equity fell 6.34% year-over-year to $14.7 billion in Q1 2026; TTM through Mar 2026 was $14.7 billion, a 6.34% decrease from a year earlier, with the FY2025 full-year figure at $14.7 billion, down 21.06% from the prior year.
- Common Equity steadied at $14.7 billion in Q1 2026 per VTRS's latest filing, from $14.7 billion in the prior quarter.
- Across five years, Common Equity topped out at $21.1 billion in Q4 2022 and bottomed at $14.7 billion in Q1 2026.
- The 5-year median for Common Equity is $19.8 billion (2024), against an average of $18.7 billion.
- Across the five-year window, Common Equity increased 8.78% in 2023 and decreased 23.11% in 2025, its largest moves.
- Year by year, Common Equity stood at $21.1 billion in 2022, then retreated by 2.87% to $20.5 billion in 2023, then fell by 8.95% to $18.6 billion in 2024, then slipped by 21.06% to $14.7 billion in 2025, then fell by 0.36% to $14.7 billion in 2026.
- Per Business Quant, the three latest VTRS Common Equity figures stand at $14.7 billion (Q1 2026), $14.7 billion (Q4 2025), and $15.2 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | 21.93 Bn |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 8.23 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 3.23 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 47.38 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 5.90 Bn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | 4.27 Mn |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 14.66 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 3.41 Bn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 6.50 Bn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 294.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.66 Bn |
| Dec 31, 2025 | 14.71 Bn |
| Sep 30, 2025 | 15.22 Bn |
| Jun 30, 2025 | 15.57 Bn |
| Mar 31, 2025 | 15.65 Bn |
| Dec 31, 2024 | 18.64 Bn |
| Sep 30, 2024 | 19.79 Bn |
| Jun 30, 2024 | 19.52 Bn |
| Mar 31, 2024 | 20.01 Bn |
| Dec 31, 2023 | 20.47 Bn |
| Sep 30, 2023 | 20.87 Bn |
| Jun 30, 2023 | 20.84 Bn |
| Mar 31, 2023 | 20.93 Bn |
| Dec 31, 2022 | 21.07 Bn |
| Sep 30, 2022 | 19.18 Bn |
| Jun 30, 2022 | 19.81 Bn |
| Mar 31, 2022 | 20.45 Bn |
| Dec 31, 2021 | 20.49 Bn |
| Sep 30, 2021 | 21.14 Bn |
| Jun 30, 2021 | 21.21 Bn |